Αποτελέσματα Αναζήτησης
26 Αυγ 2019 · For instance, by referencing the information in Figure 1, clinicians could tell their patients with stage IB MF that based on the pooled data of 6,279 patients, their chances of survival after 5 years are 85.8% in general, 88.8% in the best-case, and 82.1% in the worst-case (Figure 1).
5 Μαΐ 2023 · Still, skin-directed therapies are the most appropriate option for early-stage MF and most patients have a normal life expectancy but may suffer morbidity and impaired quality of life. In advanced disease treatment options have expanded recently.
5 Μαρ 2020 · Survival analysis demonstrated marked improvement in disease-specific and overall survival from the 1970s to 2010s. Based on systematic review of the literature, 32%–73% of patients diagnosed prior to 2000 were diagnosed with early-stage disease, as opposed to 81% of patients in the SEER 2000–2016 cohort ( P < 0.035 for all cohorts).
5 Οκτ 2023 · The treatment of MF/SS, especially advanced-stage disease, is challenging given the absence of reliably curative therapies, potential for high symptom burden with significant impact on quality of life, and frequent need for ongoing systemic therapy.
20 Σεπ 2010 · Disease progression occurred in 34%, and 26% of patients died due to MF/SS. A significant difference in survival and progression was noted for patients with early-stage disease having patches alone (T1a/T2a) compared with those having patches and plaques (T1b/T2b).
Mycosis fungoides (MF) is the most common cutaneous T-cell lymphoma that confers significant mortality in advanced-stage disease (Suzuki et al., 2010; Vollmer, 2014). Although stage-specific survival data are available from different cohorts, there have been no attempts to combine existing overall survival (OS) data in this disease (Suzuki et ...
Median survival exceeding 8 years has been observed in ECP treated patients and among complete responders, many experience durable responses which may permit, for some, weaning from CTCL-directed therapies. 178, 183-185 While patient- or disease-specific factors which may predict a response to therapy are imperfect, patients for whom treatment ...
